Atara Biotherapeutics Reports Updated Long-Term Clinical Results from a Tab-cel® Multicenter Expanded Access Protocol (EAP) Study for Patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) at the 61st American Society of Hematology (ASH) Annual Meeting

NEXT STORY
Aprea Therapeutics Presents Results From French Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual Meeting in Orlando
PREV STORY
Onconova Therapeutics Announces Data on Genomic Profiles of Higher Risk Myelodysplastic Syndromes Patients Refractory to Azacitidine Therapy Enrolled into the Pivotal INSPIRE Trial and Updated Oral Rigosertib Data Informing a Potential Adaptive Clinical Trial Design at the American Society of Hematology 2019 Annual Meeting
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Strongbridge Biopharma plc Reports First Quarter 2018 Financial Results and Provides Corporate Update

~ KEVEYIS® (dichlorphenamide) First Quarter 2018 Revenue of $3.9 Million ~ ~ Increased Full-Year ...

author_avatar
NASDAQ Market News

Novartis announces new analysis demonstrating Entresto helped preserve kidney function in patients with chronic heart failure, especially those with diabetes

author_avatar
NASDAQ Market News

OV – Oncology Venture får godkännande att utöka den pågående fas 2-studien av LiPlaCis med prostatacancerpatienter

Hoersholm, Danmark, 4 oktober 2018 - Oncology Venture A/S (Nasdaq First North Stockholm: OV.ST) ...

author_avatar
NASDAQ Market News